The study was not set up to look at any differences between the two. The Pfizer/BioNTech was available first so there is more data, but the Oxford/AstraZeneca was mostly used in the older age group. That rose to more than 85% after the second dose. He said the numbers were consistent with a relatively constant protection of about 70% at that stage. Both vaccines are being given as single doses until up to 12 weeks.
The study was not set up to look at all differences between the two vaccines. The Pfizer/BiNuclear was available first so there is more data, but the argelia vaccine is unchanged.  He relied on several epidemiological studies.  The vaccines are considered safe.
( z0 multi-sentence :snt ( z1 set-up :ARG1 ( z2 study ) :ARG2 ( z3 look :ARG0 z2 :ARG1 ( z4 differ :ARG1 ( z5 vaccine :quant 2 ) :mod ( z6 all ) ) ) :polarity - ) :snt ( z7 contrast :ARG1 ( z8 available :ARG0-of ( z9 cause :ARG1 ( z10 data :quant ( z11 more ) ) ) :ARG2 ( z12 company :name ( z13 name :op "Pfizer" ) ) :ord ( z14 ordinal-entity :value 1 ) ) :ARG2 ( z15 change :ARG1 ( z16 vaccine :mod ( z17 company :name ( z18 name :op "BiNuclear" ) ) ) :polarity - ) ) :snt ( z19 rely :ARG0 ( z20 he ) :ARG1 ( z21 study :quant ( z22 several ) :mod ( z23 epidemiology ) ) ) :snt ( z24 consider :ARG1 ( z25 safe :ARG0 ( z26 vaccine ) ) ) )
(z0 / multi-sentence
    :snt1 (z1 / set-up-03
              :ARG1 (z2 / study)
              :ARG2 (z3 / look-01
                        :ARG0 z2
                        :ARG1 (z4 / differ-02
                                  :ARG1 (z5 / vaccine
                                            :quant 2)
                                  :mod (z6 / all)))
              :polarity -)
    :snt2 (z7 / contrast-01
              :ARG1 (z8 / available-02
                        :ARG0-of (z9 / cause-01
                                     :ARG1 (z10 / data
                                                :quant (z11 / more)))
                        :ARG2 (z12 / company
                                   :name (z13 / name
                                              :op1 "Pfizer"))
                        :ord (z14 / ordinal-entity
                                  :value 1))
              :ARG2 (z15 / change-01
                         :ARG1 (z16 / vaccine
                                    :mod (z17 / company
                                              :name (z18 / name
                                                         :op1 "BiNuclear")))
                         :polarity -))
    :snt3 (z19 / rely-01
               :ARG0 (z20 / he)
               :ARG1 (z21 / study-01
                          :quant (z22 / several)
                          :mod (z23 / epidemiology)))
    :snt4 (z24 / consider-01
               :ARG1 (z25 / safe-01
                          :ARG0 (z26 / vaccine))))
The study was not set up to look at all differences between the two vaccines . The Pfizer / BiNuclear was available first so there is more data , but the argelia vaccine is unchanged . He relied on several epidemiological studies . The vaccines are considered safe .
z1 :polarity 0
z1 :ARG1 z2
z1 :ARG2 z3
z3 :ARG0 z2
z4 :mod z6
z3 :ARG1 z4
z5 :quant 3
z4 :ARG1 z5
z13 :op1 5
z18 :op1 4
z8 :ord z14
z14 :value 2
z8 :ARG0-of z9
z10 :quant z11
z9 :ARG1 z10
z7 :ARG1 z8
z8 :ARG2 z12
z12 :name z13
z17 :name z18
z16 :mod z17
z15 :ARG1 z16
z7 :ARG2 z15
z15 :polarity 1
z0 :snt2 z7
z0 :snt1 z1
z19 :ARG0 z20
z0 :snt3 z19
z21 :mod z23
z21 :quant z22
z19 :ARG1 z21
z0 :snt4 z24
z24 :ARG1 z25
z25 :ARG0 z26